Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report) and keeping the price target at $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Justin Walsh has given his Buy rating due to a combination of factors surrounding Perspective Therapeutics’ recent clinical advancements and strategic developments. The company has made significant progress in its Pb-212-VMT-α-NET program, having reached an agreement with the FDA to proceed with Cohort 3 of their Phase I/IIa trial. This cautious approach, which includes weight-based dosing for lighter patients, is seen as a positive step given the promising anti-tumor activity observed in earlier cohorts without reported renal toxicity.
Furthermore, the dosimetry study of Pb-203-VMT-α-NET showed a favorable tumor-to-kidney absorbed dose ratio, which supports the potential efficacy and safety of the treatment. The ongoing development of Ga-68-PSV377 as a diagnostic tool targeting fibroblast activation protein further enhances the company’s pipeline. These clinical updates and strategic moves are expected to strengthen Perspective Therapeutics’ competitive position, justifying the Buy rating and the $18 price target.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CATX in relation to earlier this year.